Table 3.
Recoveries of belinostat and its metabolites from human plasma and their respective ion suppressions in human plasma extract, with coefficients of variation (CV).
| Analyte | Concentration (ng/mL) | Recovery (%) | CV (%) | Ion suppression (%) | CV (%) |
|---|---|---|---|---|---|
| Belinostat | 30 (QCLL) | 69.9 | 23.5 | −19.8 | 10.4 |
| 100 (QCL) | 82.7 | 7.1 | −11.5 | 7.2 | |
| 2500 (QCM | 84.9 | 11.0 | −15.1 | 4.7 | |
| 4000 (QCH) | 85.1 | 5.3 | −4.0 | 3.6 | |
|
| |||||
| Belinostat-glucuronide | 30 (QCLL) | 80.8 | 16.2 | −12.2 | 6.9 |
| 100 (QCL) | 78.3 | 12.9 | −17.2 | 11.9 | |
| 2500 (QCM | 85.4 | 4.9 | −3.6 | 7.5 | |
| 4000 (QCH) | 85.8 | 7.0 | −3.4 | 8.1 | |
|
| |||||
| Methyl-belinostat | 30 (QCLL) | 84.8 | 14.9 | 7.8 | 11.9 |
| 100 (QCL) | 86.4 | 5.9 | 8.8 | 6.0 | |
| 2500 (QCM | 84.6 | 11.4 | −6.2 | 7.5 | |
| 4000 (QCH) | 89.5 | 4.7 | 3.5 | 2.7 | |
|
| |||||
| M21 | 30 (QCLL) | 75.0 | 20.2 | −13.1 | 21.1 |
| 100 (QCL) | 80.3 | 17.4 | 0.0 | 16.2 | |
| 2500 (QCM | 90.7 | 12.4 | 4.3 | 8.9 | |
| 4000 (QCH) | 94.9 | 9.9 | 8.0 | 8.6 | |
|
| |||||
| M24 | 30 (QCLL) | 79.3 | 22.4 | −5.0 | 35.4 |
| 100 (QCL) | 84.0 | 36.1 | −13.5 | 21.1 | |
| 2500 (QCM | 88.0 | 16.2 | −1.7 | 4.9 | |
| 4000 (QCH) | 92.8 | 7.4 | 4.9 | 6.8 | |
|
| |||||
| M26 | 30 (QCLL) | 78.4 | 10.3 | 1.3 | 15.6 |
| 100 (QCL) | 64.4 | 19.9 | −43.3 | 19.4 | |
| 2500 (QCM | 81.4 | 10.7 | 0.99 | 7.4 | |
| 4000 (QCH) | 88.3 | 9.3 | 0.83 | 7.3 | |
N=3, for each concentration.